MX2009009141A - Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano. - Google Patents
Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano.Info
- Publication number
- MX2009009141A MX2009009141A MX2009009141A MX2009009141A MX2009009141A MX 2009009141 A MX2009009141 A MX 2009009141A MX 2009009141 A MX2009009141 A MX 2009009141A MX 2009009141 A MX2009009141 A MX 2009009141A MX 2009009141 A MX2009009141 A MX 2009009141A
- Authority
- MX
- Mexico
- Prior art keywords
- azabicyclo
- crystalline forms
- crystalline
- salt forms
- octane compound
- Prior art date
Links
- -1 8-azabicyclo[3.2.1]octane compound Chemical class 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000051367 mu Opioid Receptors Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- 108020001612 μ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En la invención se provee una sal cristalina de sulfato de 3-endo-(8-{2-[ciclohexilmetil-((S)-2,3-dihidroxi-propionil)amino] etil}-8-aza-biciclo[3,2,1)oct-3-il)benzamida o un solvato de ésta. En la invención también se proveen composiciones farmacéuticas que comprenden estas formas de sales cristalinas, métodos para usar estas formas de sales cristalinas para tratar enfermedades asociadas con la actividad del receptor de opiáceos mu y procesos útiles para preparar estas formas de sales cristalinas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90409007P | 2007-02-28 | 2007-02-28 | |
| PCT/US2008/002583 WO2008106159A1 (en) | 2007-02-28 | 2008-02-27 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009141A true MX2009009141A (es) | 2009-09-03 |
Family
ID=39620376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009141A MX2009009141A (es) | 2007-02-28 | 2008-02-27 | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano. |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US7943772B2 (es) |
| EP (1) | EP2132204B1 (es) |
| JP (2) | JP5512289B2 (es) |
| KR (1) | KR101480530B1 (es) |
| CN (1) | CN101616916B (es) |
| AR (2) | AR065554A1 (es) |
| AU (1) | AU2008219615B2 (es) |
| BR (1) | BRPI0807974B8 (es) |
| CA (1) | CA2678073C (es) |
| CL (1) | CL2008000573A1 (es) |
| CO (1) | CO6220856A2 (es) |
| CY (1) | CY1115077T1 (es) |
| DK (1) | DK2132204T3 (es) |
| ES (1) | ES2402031T3 (es) |
| HR (1) | HRP20130193T1 (es) |
| IL (1) | IL200131A (es) |
| MX (1) | MX2009009141A (es) |
| MY (1) | MY148318A (es) |
| NZ (1) | NZ578871A (es) |
| PL (1) | PL2132204T3 (es) |
| PT (1) | PT2132204E (es) |
| RU (1) | RU2458061C2 (es) |
| SI (1) | SI2132204T1 (es) |
| TW (1) | TWI409067B (es) |
| WO (1) | WO2008106159A1 (es) |
| ZA (1) | ZA200905832B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型 |
| TWI415850B (zh) * | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備mu類鴉片受體拮抗劑之中間物的方法 |
| WO2009029253A1 (en) * | 2007-08-27 | 2009-03-05 | Theravance, Inc. | Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| DE602008005771D1 (de) * | 2007-08-27 | 2011-05-05 | Theravance Inc | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten |
| TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物 |
| EP2185553B1 (en) * | 2007-08-27 | 2012-06-27 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| JP5797655B2 (ja) * | 2009-09-18 | 2015-10-21 | アドラー・コーポレーション | 消化管障害のためのオピオイド受容体アンタゴニストの使用 |
| HRP20200432T1 (hr) | 2015-04-02 | 2020-06-12 | Theravance Biopharma R&D Ip, Llc | Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US6900228B1 (en) | 1998-03-10 | 2005-05-31 | Research Triangle Institute | Opiate compounds, methods of making and methods of use |
| GB9810671D0 (en) | 1998-05-18 | 1998-07-15 | Pfizer Ltd | Anti-pruritic agents |
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB9912410D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
| US6467084B1 (en) * | 1999-12-16 | 2002-10-15 | Emware, Inc. | Systems and methods for reprogramming an embedded device with program code using relocatable program code |
| US6552036B2 (en) | 2000-03-03 | 2003-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| US20020025948A1 (en) | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| AP1816A (en) | 2001-10-22 | 2008-01-04 | Pfizer Prod Inc | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists. |
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| US20040204453A1 (en) | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
| MXPA05011070A (es) | 2003-04-14 | 2005-12-12 | Pfizer Prod Inc | Derivados de 3-azabiciclo [3.2.1] octano. |
| US7056930B2 (en) * | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
| JP2006523673A (ja) | 2003-04-15 | 2006-10-19 | ファイザー・プロダクツ・インク | オピオイド受容体活性を有する3−ベンズヒドリリデン−8−アザ−ビシクロ[3.2.1]オクタン誘導体 |
| US6992090B2 (en) | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| EP1737853A1 (en) | 2004-02-03 | 2007-01-03 | Janssen Pharmaceutica N.V. | 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives |
| US7087749B2 (en) | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| CN101534827A (zh) | 2006-11-07 | 2009-09-16 | 尼克塔治疗亚拉巴马公司 | 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药 |
| TWI409067B (zh) * | 2007-02-28 | 2013-09-21 | Theravance Inc | 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型 |
-
2008
- 2008-02-15 TW TW097105472A patent/TWI409067B/zh active
- 2008-02-25 CL CL200800573A patent/CL2008000573A1/es unknown
- 2008-02-27 CA CA2678073A patent/CA2678073C/en active Active
- 2008-02-27 MY MYPI20093401A patent/MY148318A/en unknown
- 2008-02-27 RU RU2009135834/04A patent/RU2458061C2/ru active
- 2008-02-27 DK DK08726162.4T patent/DK2132204T3/da active
- 2008-02-27 JP JP2009551709A patent/JP5512289B2/ja active Active
- 2008-02-27 BR BRPI0807974A patent/BRPI0807974B8/pt not_active IP Right Cessation
- 2008-02-27 PT PT87261624T patent/PT2132204E/pt unknown
- 2008-02-27 US US12/072,534 patent/US7943772B2/en active Active
- 2008-02-27 HR HRP20130193AT patent/HRP20130193T1/hr unknown
- 2008-02-27 MX MX2009009141A patent/MX2009009141A/es active IP Right Grant
- 2008-02-27 SI SI200830928T patent/SI2132204T1/sl unknown
- 2008-02-27 KR KR1020097020094A patent/KR101480530B1/ko active Active
- 2008-02-27 NZ NZ578871A patent/NZ578871A/en not_active IP Right Cessation
- 2008-02-27 PL PL08726162T patent/PL2132204T3/pl unknown
- 2008-02-27 CN CN2008800059690A patent/CN101616916B/zh active Active
- 2008-02-27 EP EP08726162A patent/EP2132204B1/en active Active
- 2008-02-27 WO PCT/US2008/002583 patent/WO2008106159A1/en not_active Ceased
- 2008-02-27 AU AU2008219615A patent/AU2008219615B2/en not_active Ceased
- 2008-02-27 ES ES08726162T patent/ES2402031T3/es active Active
- 2008-02-28 AR ARP080100850A patent/AR065554A1/es not_active Application Discontinuation
-
2009
- 2009-07-29 IL IL200131A patent/IL200131A/en active IP Right Grant
- 2009-08-21 ZA ZA200905832A patent/ZA200905832B/xx unknown
- 2009-08-26 CO CO09089674A patent/CO6220856A2/es active IP Right Grant
-
2011
- 2011-04-06 US US13/081,162 patent/US8247555B2/en active Active
-
2012
- 2012-07-17 US US13/550,781 patent/US8536335B2/en active Active
-
2013
- 2013-04-08 CY CY20131100293T patent/CY1115077T1/el unknown
- 2013-05-10 JP JP2013099851A patent/JP2013151564A/ja not_active Withdrawn
- 2013-08-13 US US13/965,691 patent/US8816091B2/en active Active
-
2014
- 2014-07-16 US US14/333,003 patent/US9290491B2/en active Active
-
2016
- 2016-02-10 US US15/040,191 patent/US9949963B2/en active Active
-
2017
- 2017-07-31 AR ARP170102183A patent/AR109224A2/es unknown
-
2018
- 2018-03-13 US US15/919,678 patent/US10426766B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009141A (es) | Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano. | |
| TW200800981A (en) | 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists | |
| MX2010002171A (es) | Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu. | |
| ATE502939T1 (de) | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten | |
| TW200643020A (en) | Crystalline form of a quinolinone-carboxamide compound | |
| IL195891A0 (en) | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use od same in therapeutics | |
| MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
| MX2009006018A (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos. | |
| WO2007098826A3 (en) | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | |
| HK1197240A1 (en) | New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities | |
| MY139720A (en) | Micronized crystalline tiotropium bromide | |
| IL195818A0 (en) | Derivatives of 2-benzoyl-imidazopyridines, preparation ,method thereof and use of same in therapeutics | |
| BRPI0821611A8 (pt) | Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu | |
| MX2010000813A (es) | Proceso para preparar un intermediario para los antagonistas de los receptores opioides mu. | |
| PL1869038T3 (pl) | Podstawione pochodne 5,6,7,8-tetrahydro-imidazo[1,2-a]pirydyn-2-yloaminy i ich zastosowanie do wytwarzania środków leczniczych | |
| TW200640921A (en) | Crystalline form of an indazole-carboxamide compound | |
| EP4616915A3 (en) | Ecopipam for treatment of tourettes syndrome | |
| MY179041A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
| IL192864A0 (en) | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | |
| ZA200807467B (en) | 8-Azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | |
| TH120971A (th) | รูปแบบเชิงผลึกของสารประกอบ 8-อะซาไบไซโคล[3.2.1]ออกเทน | |
| WO2009010492A3 (en) | Combinations comprising telmisartan and an anticholinergic such as tiotropium or a glycopyrronium salt for the treatment of respiratory diseases such as copd or asthma | |
| HK1161220A (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |